evans blue has been researched along with Cirrhosis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| French, CJ; Schneider, DJ; Sobel, BE; Zaman, AK | 1 |
| Hoey, AJ; Laws, N; Loch, D; Trebbin, A; Van Erp, C | 1 |
| Adamo, CM; Adams, ME; Beavo, JA; Froehner, SC; Percival, JM; Whitehead, NP | 1 |
3 other study(ies) available for evans blue and Cirrhosis
| Article | Year |
|---|---|
A profibrotic effect of plasminogen activator inhibitor type-1 (PAI-1) in the heart.
Topics: Animals; Blood Pressure; Body Weight; Creatine Kinase; Echocardiography, Doppler; Evans Blue; Fibrosis; Heart Ventricles; Mice; Mice, Inbred C57BL; Mice, Transgenic; Myocardial Infarction; Myocardium; Organ Size; Plasminogen Activator Inhibitor 1; Ventricular Function, Left | 2009 |
Timeline of cardiac dystrophy in 3-18-month-old MDX mice.
Topics: Aging; Animals; Aorta, Thoracic; Cardiomyopathies; Coloring Agents; Evans Blue; Fibrosis; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Inbred mdx; Muscular Dystrophy, Duchenne; Myocardium; Phosphorylation; RNA, Messenger; Smad2 Protein; Time Factors; Transforming Growth Factor beta | 2010 |
Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy.
Topics: Animals; Creatine Kinase; Cyclic GMP; Diaphragm; Disease Models, Animal; Evans Blue; Fibrosis; Male; Mice; Mice, Inbred C57BL; Mice, Inbred mdx; Muscle Contraction; Muscle Fatigue; Muscle Weakness; Muscular Dystrophy, Duchenne; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones | 2012 |